And at all of those places, I discuss science and science-related tools, some of which overlaps with the content of the Huberman Lab podcast, but much of which is distinct from the content of the Huberman Lab podcast
CJC-1295, a synthetic analog of growth hormonereleasing hormone (GHRH), was developed in the early 2000s to extend the half-life and activity of natural GHRH fragments for research into growth hormone and IGF-1 pathways
A clinical evaluation involving 216 volunteers (December 2024) states: Did You Know
By targeting the brains hunger and satiety centers, this treatment can lead to: This therapy may be right for: Note: This therapy is not for individuals with a history of medullary thyroid cancer, pancreatitis, or specific endocrine disorders
doi: 10.1016/S1473-3099(21)00485-0 6 AldiniG.AltomareA.BaronG.VistoliG.CariniM.BorsaniL.et al